Diabetik retinopatide güncel tıbbi tedavi yaklaşımları

BATOĞLU, Figen; POLAT, Burcu

Diabetik retinopatide güncel tıbbi tedavi yaklaşımları

Burcu POLAT, (Ankara Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Figen BATOĞLU (Ankara Üniversitesi, Tıp Fakültesi, Göz Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Retina-Vitreus

9 0

Yıl: 2007 Cilt: 15 Sayı: 3 Sayfa Aralığı: 153 - 159 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Diabetik retinopatide güncel tıbbi tedavi yaklaşımları

Öz:

Diabetik retinopati (DR), günümüzde gelişmiş toplumlarda körlüğün en önemli nedenidir. Hastalığın süresi uzadıkça komplikasyon riski artmakta ve eşlik eden sistemik faktörler ilerlemesini hızlandırmaktadır. Bu nedenle öncelikle sistemik durumun düzenlenmesi gerekmektedir. Diabetik retinopati tedavisinde lazer fotokoagülasyon ve vitreoretinal cerrahinin yanı sıra son yıllarda medikal tedavide gelişmeler sağlanmıştır. Antioksidanlar, aldoz redüktaz ve ileri glikolizasyon son ürün inhibitörleri, protein kinaz C inhibitörleri, vasküler endotelyal büyüme faktörü (VEGF) inhibitörleri ve intravitreal kortikosteroid enjeksiyonları medikal tedavide kullanılan ajanlardır. Medikal tedavideki gelişmeler ile diabetik retinopati gelişimi ve ilerleyişinin yavaşlatılması sağlanmaktadır.Bu derlemede, güncel literatür bilgileri ışığında diabetik retinopatide tıbbi tedavi yaklaşımları gözden geçirilmiştir.

Anahtar Kelime: Steroidler Diabetik retinopati Vitreus içi enjeksiyon Vasküler endotelyal büyüme faktörleri Aldehit redüktaz Protein kinaz inhibitörleri Triamsinolon asetonit Protein kinaz C

Konular: Göz Hastalıkları

New medical treatment approaches in diabetic retinopathy

Öz:

Diabetic retinopathy (DR) is one of the most important causes of blindness in developed societies. The risk of complications increases by the duration of disease and some coexisting systemic disorders affect the progression. Therefore, first step in the treatment of DR is regulation of systemic risk factors. Although laser photocoagulation and vitreoretinal surgery are the main treatment modalities of DR, medical approaches have advanced, currently. Antioxidants, inhibitors of aldose reductase, advanced glycation end products, protein kinase C and vascular endothelial growth factor (VEGF) inhibitors and intravitreal corticosteroid injections are medical treatment modalities of DR. The advances in medical approaches can retard the development and progression of DR.In this study, new medical treatment approaches were discussed with the review of recent literature.

Anahtar Kelime: Protein Kinase Inhibitors Triamcinolone Acetonide Protein Kinase C Steroids Diabetic Retinopathy Intravitreal Injections Vascular Endothelial Growth Factors Aldehyde Reductase

Konular: Göz Hastalıkları

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Bibliyografik

1. Bursell SE, Clermont AC, Aiello LP et al.: High-dose vitamin E supplementation normalizes retinal blood flow and creatinine clearance in patients with type 1 diabetes. Diabetes Care. 1999;22:1245-1251.
2. Di Leo MA, Ghirlanda G: Potential therapeutic effect of antioxidants in experimental diabetic retina: a comparison between chronic taurine and vitamin E plus selenium supplementations. Fren Radic Res. 2003;37:323-330.
3. A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Sorbinil Retinopathy Trial Research Group. Arch Ophthalmol. 1990;108:1234-1244.
4. Hammes HP, Martin S, Federlin K et al.: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991;88:11555-11558.
5. Kern TS, Engerman RL: Pharmacological inhibition of diabetic retinopathy: aminoguanidine and aspirin. Diabetes. 2001;50:1636-1642.
6. Freedman BI, Wuerth JP, Cartwright K et al.: Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials. 1999;20:493-510.
7. Ishii H, Jirousek MR, Koya D et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 1996;272;728-731.
8. The PKC-DRS Study Group: The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes. 2005;54:2188-2297.
9. Strom C, Sander B, Klemp K et al.: Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci. 2005;46:3855-3858.
10. Aiello LP, Clermont A, Arora V, et al.: Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci. 2006;47:86-92.
11. Peter A. Campochiaro, The C99-PKC412-003 Study Group: Reduction of Diabetic Macular Edema by Oral Administration of the Kinase Inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004;45:922-931.
12. Entezari M, Ahmadieh H, Dehghan MH et al.: Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial. Eur J Ophthalmol. 2005;15:746-750.
13. Verma LK, Vivek MB, Kumar A et al.:A prospective controlled trial to evaluate the adjunctive role of posterior subtenon triamcinolone in the treatment of diffuse diabetic macular edema. J Ocular Pharm and Therapeutics. 2004;20:277-284.
14. Javadzadeh A.: The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series. BMC Ophthalmol. 2006;6:15.
15. Machemer R, Sugita G, Tano Y.: Treatment of intraocular proliferations with intravitreal steroids. Tr Am Ophth Soc. 1979;77:171- 180.
16. Jonas JB, Sofker A.: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427.
17. Bonini-Filho MA, Jorge R, Barbosa JC et al.: Intravitreal injection versus sub-Tenon’s infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial.: Invest Ophthalmol Vis Sci. 2005;46:3845-3849.
18. Martidis A, Duker JS, Greenberg PB et al.: İntravitreal Triamcinolone for Refractory Diabetic Macular Edema. Ophthalmology. 2002;109:920-927.
19. Massin P, Audren F, Haouchine B et al.: Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218- 224.
20. Batıoğlu F, Özmert E, Parmak N, Çelik S: Two-Year Results Of İntravitreal Triamcinolone Acetonide Injection For The Treatment Of Diabetic Macular Edema. Int Ophthalmol. 2007; Apr 24 (E-pub ahead of print)
21. Zacks, David N. MD, PhD; Johnson, Mark W. MD: Combined İntravitreal İnjection of Triamcinolone acetonide and Panretinal Photocoagulation for concomitant Diabetic Macular Edema and Proliferative Diabetic Retinopathy. Retina. 2005;25:135-140.
22. Zein WM; Noureddin BN, Jurdi FA et al.: Panretinal Photocoagulation and Intravitreal Triamcinolone Acetonide for the Management of Proliferative Diabetic Retinopathy with Macular Edema. Retina. 2006;26:137-142.
23. Teresio Avitabile, MD; Antonio Longo, MD; Alfredo Reibaldi, MD.: Intravitreal Triamcinolone Compared With Macular Laser Grid Photocoagulation for the Treatment of Cystoid Macular Edema. Am J Ophthalmol. 2005;140;695-702.
24. Kang SW, Sa HS, Cho HY et al.: Macular Grid Photocoagulation After Intravitreal Triamcinolone Acetonide for Diffuse Diabetic Macular Edema. Arch Ophthalmol. 2006;124;653-658.
25. Mruthyunjaya P, Khalatbari D, Yang P et al.: Efficacy of lowrelease- rate fluocinolone acetonide intravitreal implants to treat experimental uveitis. Arch Ophthalmol. 2006;124:1012-1018.
26. Mohammad DA, Sweet BV, Elner SG.: Retisert: is the new advance in treatment of uveitis a good one? Ann Pharmacother. 2007;41:449-454.
27. Kuppermann BD, Blumenkranz MS, Haller JA et al.: for the Dexamethasone DDS Phase II Study Group:Randomized controlled study of an intravitreous Dexamethasone Drug Delivery System in patients with persistent macular edema. Arch Ophthalmol. 2007;125;309-317.
28. Qaum T, Xu Q, Joussen AM et al.: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci. 2001;42:2408-2413.
29. Haritoglou C, Kook D, Neubauer A et al.: İntravitreal Bevacizumab (Avastin) Therapy for Persistent Diffuse Diabetic Macular Edema. Retina. 2006;26:999-1005.
30. Cunningham ET, Jr. Adamis AP, Altaweel M et al.: A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.. Ophthalmology. 2005;112:1747-1757.
31. Chun DW, Heier JS, Topping TM et al.: A Pilot Study of Multiple İntravitreal Injections of Ranibizumab in Patients with Center –Involving Clinically Significant Diabetic Macular Edema. Ophthalmology. 2006;113;1706-1712.
32. Dodson PM, Gibson JM. Long term follow-up of and underlying medical conditions in patients with diabetic exudative maculopathy. Eye. 1991;5:699-703.
33. Chew EY, Klein ML, Ferris FL, Remaley NA, et al.: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) report 22. Arch Ophthalmol. 1996;114:1079-1084.
34. Dale J, Farmer J, Jones AF, et al.: Diabetic ischaemic and exudative maculopathy: are their risk factors different? Diab Med.2000;17:47.
35. van der Pijl JW, van der Woude FJ, Swart W et al.: Effect of danaparoid sodium on hard exudates in diabetic retinopathy. Lancet. 1997;350:1743-1745.
36. Berthet P, Farine JC, Barras JP.: Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int J Clin Pract. 1999;53:631-636.
37. Haas A, Trummer G, Eckhardt M et al.: Effect of calcium dobesilate on progression of diabetic retinopathy. Klin Monatsbl Augenheilkd. 1995;207:17-21.
38. Ribeiro ML, Seres AI, Carneiro AM et al.: Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol. 2006;9.
39. Berman DH,Friedman DH.: Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina. 1994;14:1-5.
40. Hernández C, Fonollosa A, Garcia-Ramirez M et al.: Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028-2033.
41. Janknecht P, Schumann P, Hansen LL.: Reduction of retinal exudates in diabetic retinopathy after heparin-induced extracorporal LDL-precipitation (HELP). A case report. Eur J Ophthalmol. 1996;6:340-342.
42. Matsuo T.: Disappearance of diabetic macular hard exudates after hemodialysis introduction. Acta Med Okayama. 2006;60;201-205.
43. Early Treatment Diabetic Retinopathy Study Research Group.: Effects of Aspirin Treatment on Diabetic Retinopathy. ETDRS Report Number 8. Ophthalmology. 1991;98:757-765.
44. Chaturvedi N, Sjolie AK, Stephenson JM et al.: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet. 1998;351:28-31.
45. Grant MB, Mames RN, Fitzgerald C et al.: The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy; a randomized controlled study. Diabetes Care. 2000;23:504-509.
46. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group.: The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology.2001;108:2266-2272.

APA	POLAT B, BATOĞLU F (2007). Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. , 153 - 159.
Chicago	POLAT Burcu,BATOĞLU Figen Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. (2007): 153 - 159.
MLA	POLAT Burcu,BATOĞLU Figen Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. , 2007, ss.153 - 159.
AMA	POLAT B,BATOĞLU F Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. . 2007; 153 - 159.
Vancouver	POLAT B,BATOĞLU F Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. . 2007; 153 - 159.
IEEE	POLAT B,BATOĞLU F "Diabetik retinopatide güncel tıbbi tedavi yaklaşımları." , ss.153 - 159, 2007.
ISNAD	POLAT, Burcu - BATOĞLU, Figen. "Diabetik retinopatide güncel tıbbi tedavi yaklaşımları". (2007), 153-159.

APA	POLAT B, BATOĞLU F (2007). Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. Retina-Vitreus, 15(3), 153 - 159.
Chicago	POLAT Burcu,BATOĞLU Figen Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. Retina-Vitreus 15, no.3 (2007): 153 - 159.
MLA	POLAT Burcu,BATOĞLU Figen Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. Retina-Vitreus, vol.15, no.3, 2007, ss.153 - 159.
AMA	POLAT B,BATOĞLU F Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. Retina-Vitreus. 2007; 15(3): 153 - 159.
Vancouver	POLAT B,BATOĞLU F Diabetik retinopatide güncel tıbbi tedavi yaklaşımları. Retina-Vitreus. 2007; 15(3): 153 - 159.
IEEE	POLAT B,BATOĞLU F "Diabetik retinopatide güncel tıbbi tedavi yaklaşımları." Retina-Vitreus, 15, ss.153 - 159, 2007.
ISNAD	POLAT, Burcu - BATOĞLU, Figen. "Diabetik retinopatide güncel tıbbi tedavi yaklaşımları". Retina-Vitreus 15/3 (2007), 153-159.